EMA: Questions and answers on the review of the marketing authorisations for topical formulations of ketoprofen

The European Medicines Agency has completed a review of the safety and effectiveness of ketoprofen-containing medicines used topically (on the skin). The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of topical ketoprofen continue to outweigh its risks, but that further measures should be put in place to minimise the risk of adverse skin reactions.